|Basic InformationMore InformationLatest News|Group Urges Tougher Limits on Chemical in Shampoos, Cosmetics18 Percent Increase Projected in Primary Care Demand by 2023Why Patients Leave the Hospital Against Doctor's OrdersRaise the Smoking Age to 21? Most Kids Fine With ThatComprehensive Audiologic Care Feasible in Free Clinic ModelMany Tanning Salons Defy Legal Age Limits on UsersLifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyFDA Puts Brakes on Rule Requiring New 'Nutrition Facts' LabelCardiac Arrest? Someday, Drones May Come to Your RescueSAMHSA: 9.8 Million U.S. Adults Have Serious Mental IllnessFDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From MarketHealth System Sees Success With E-Visits Via Patient PortalOvercharging Common in U.S. Emergency RoomsAdvocating for a Loved OneHigh Costs for Myeloma Patients Not Getting Low-Income SubsidyGetting Bedbugs Out of Nursing Homes, Apartment Buildings - for GoodCosts of ER Treatments a Mystery to Many DocsNew Bill Intends to Repeal Limits on Physician-Owned HospitalsTechnology Can Help Patients Facing Routine DecisionsKidneys From Deceased Diabetics Might Ease Organ Shortage: StudyElements of a Patient-Centered Hospital Room IdentifiedCan Tracking Germs in One Hospital Make All Hospitals Safer?Chances of Successful CPR Dwindle as Seniors AgeNew FDA Head Outlines 'Forceful Steps' Against Opioid CrisisChecking Patient's Drug History May Help Curb Opioid AbuseAt Major Teaching Hospitals, Lower Death RatesAmericans Skeptical of Corporate-Backed Health ResearchToo Many Americans Still Go Without Cancer ScreeningsBlack, Hispanic Americans Less Likely to See a NeurologistSome Lead Poisoning Tests May Be FaultyYour Doctor's Age Might Affect Your CareMany U.S. Travelers Skip Measles Shots, Despite Infection RiskPatients Satisfied With Telehealth Primary Care VisitsNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalNo Routine Screening for Thyroid Cancer: Expert PanelPAS: Internet Info Can Lower Parent Trust in Doctors' DiagnosisFDA Warns of Tattoo DangersBystander CPR Not Only Saves Lives, It Lessens Disability: StudyMore Starring Roles for Booze in Kids' Movies, Study FindsMental Health Myths Abound in the U.S.Half of U.S. Docs Get Payments From Drug, Device Industries: StudyAMA Urges Doctors to Talk About Safe Opioid Storage, DisposalRoutine Blood Tests Can Harm Patient CareApril 29 Is National Prescription Drug Take Back DayFDA Warns 14 Companies on Bogus Cancer 'Cures'Price Transparency Intervention Doesn't Cut Lab Test OrdersMost Patients Not Shy About Revealing Sexual OrientationNYC to Raise Cigarette Prices to Highest in the United StatesQuestions and AnswersLinksBook Reviews
High Costs for Myeloma Patients Not Getting Low-Income Subsidy
Updated: May 31st 2017
WEDNESDAY, May 31, 2017 (HealthDay News) -- There is a substantial financial burden for Medicare beneficiaries with myeloma who do not receive a low-income subsidy (LIS) for orally-administered anticancer therapy, according to a study published online May 25 in the Journal of Clinical Oncology.
Adam J. Olszewski, M.D., from Rhode Island Hospital in Providence, and colleagues identified Part D beneficiaries diagnosed with myeloma in 2007 to 2011. In multivariable models adjusted for sociodemographic and clinical characteristics, the authors analyzed the correlation between LIS and use of immunomodulatory drug (IMiD)-based therapy, delays between IMiD refills, and select health outcomes.
The researchers found that 41 percent of 3,038 beneficiaries received first-line IMiDs. For the first IMiD prescription, the median out-of-pocket cost was $3,178 and $3 for LIS nonrecipients and recipients, respectively; for the first year of therapy the corresponding median costs were $5,623 and $6. LIS receipt correlated with a 32 percent increased probability of receiving IMiDs among beneficiaries aged 75 to 84 years, and, in all groups, with a significantly lower risk of delays between refills (adjusted relative risk, 0.54). There was no significant difference in duration of therapy for LIS recipients and nonrecipients (median, 7.6 months). Significantly fewer emergency department visits and hospitalizations were seen for patients treated with IMiDs versus those receiving bortezomib without IMiDs.
"Medicare beneficiaries with myeloma who do not receive LISs face a substantial financial barrier to accessing orally administered anticancer therapy, warranting urgent attention from policymakers," the authors write.
Several authors disclosed financial ties to the biopharmaceutical industry.
Full Text (subscription or payment may be required)
This article: Copyright © 2017 HealthDay. All rights reserved.